University of Illinois at Chicago
Announcement of a Sole Source Purchase
Renewal entered into with:Vendor: CardioFocus, Inc.
Amount: An estimated $450,000
Renewal: 1 of 2, 7/1/2020 through 6/30/2021
Pricing Changes:
None
Service/Product Changes:
None
Sole Source Status:
Yes, this procurement remains a sole source.
Potential Future Renewals:
$450,000
The Chief Procurement Officer for this procurement is now Ben Bagby.
The State Purchasing Officer for this procurement is now Catherine Bradbury.
The University has taken into account 30 ILCS 575/8i of the BEP Act in conducting this renewal.
The University award process may be delayed up to thirty days as this award goes through a state approval process.
Awarded to:Vendor: CardioFocus, Inc., Marlborough, MA
Amount: An estimated $1,350,000
Terms:
An estimated start date of 5/15/2017 through 6/30/2020, 36 months
Renewals:
2 one-year
Potential Future Renewals:
$900,000
The University award process may be delayed up to thirty days as this award goes through a state approval process.
The hearing has been cancelled since no vendors registered to attend or submitted comments regarding this notice.
The State Purchasing Officer for this procurement is now Shirley Webb.
First published Friday, April 14, 2017
The University awarded a contract for visual guid Laser Pulmonary Vein Isolation Abla. to CardioFocus, Inc., Marlborough, MA, for an estimated $1,350,000.
The CardioFocus HeartLight® Endoscopic Ablation System (EAS) is the only FDA approved device using laser energy to isolate the pulmonary veins (PV). Also unique to our system is a compliant balloon and direct tissue visualization via an endoscope to aid in lesion placement.
Electrical isolation of the PV?s prevents premature atrial beats from being conducted to the left atrium and initiating AFib. The HeartLight® Endoscopic Ablation System is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. In drug refractory, paroxysmal atrial fibrillation (PAF), patients have tried and failed or not tolerated drug therapy where AFib begins suddenly and then stops on its own. Symptoms can be mild or severe. AFib stops within about a week, but usually in less than 24 hours. More than 25 percent of people with paroxysmal AFib will go on to develop persistent or chronic atrial fibrillation.
The University has determined that this purchase is only economically available from this source because the item or service is copyrighted or patented and is not available except from the holder of the copyright or patent.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
State Purchasing Officer - Aaron M. Finder
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.
